GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
The FDA removed black box warnings related to breast cancer, cardiovascular disease and dementia from six hormone replacement therapies for menopausal women, following a comprehensive review of scientific literature.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06396390 |
Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes |
NOT_YET_RECRUITING | PHASE4 |
| NCT05903131 |
Uterine Preservation Via Lifestyle Transformation |
RECRUITING | PHASE2 |
| NCT05244811 |
Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills |
UNKNOWN | PHASE3 |
| NCT02969590 |
Regulation of Cervical Mucus Secretion |
COMPLETED | PHASE4 |
| NCT01966575 |
Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate |
WITHDRAWN | PHASE4 |
| NCT01718444 |
Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study) |
TERMINATED | NA |
